The adenosine pathway in immuno-oncology

Nature Reviews Clinical Oncology, Published online: 08 June 2020; doi:10.1038/s41571-020-0382-2Signalling induced by extracellular adenosine (eADO) can suppress antitumour immunity through multiple mechanisms. Herein, the authors review the pathophysiological functions of eADO in cancer and the related prognostic implications. They discuss the associated opportunities for eADO pathway-targeted immunotherapy, highlighting potential limitations and the scope for combination and biomarker-based strategies. The data emerging from oncology clinical trials of the diverse range of therapies that have been developed to target the eADO signalling pathway are also described.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research